Clin2
NCT07266584Possibly a fitRecruiting

Retinal implant for central vision loss in inherited eye disease

Stargardt DiseaseRetinitis Pigmentosa (RP)Inherited Retinal Degeneration

Part of Eyes & vision, Genetic & congenital clinical trials.

This trial tests a new implant (PRIMA) placed under the retina to help restore central vision in people with inherited retinal degeneration. If you have very poor central vision and a large enough area of retinal damage, this device may help you see better.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
5 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 or older.
  • You have a confirmed inherited retinal disease that affects the central vision in both eyes.
  • Your vision in the eye to be treated is 20/320 or worse (very poor central vision).
  • The damaged area in the center of your retina is at least the size of the implant (about 4.5 mm²).
  • You are willing and able to attend all follow-up visits and sign the consent form.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07088705Enrolling by invitation
Subthreshold laser for retinitis pigmentosa

This trial tests a gentle laser treatment (SML) for people with retinitis pigmentosa (RP), an inherited eye disease that slowly causes vision loss. The goal is to see if the laser can help slow or improve vision problems like night blindness and tunnel vision.

Szczecin
NCT07710196Not yet recruiting· Phase 3
Testing NPI-001 for preserving vision in Usher syndrome

This trial tests an oral medication (NPI-001) to see if it can preserve the light-sensing cells in the retina for people with retinitis pigmentosa caused by Usher syndrome. It lasts 24 months and requires several eye exams to monitor changes.

NCT07774975Not yet recruiting· Phase 1
Pitavastatin eye injection for retinitis pigmentosa

This study tests a new eye injection containing pitavastatin, a drug normally used for cholesterol, wrapped in tiny particles. The goal is to see if it is safe and if it can help slow vision loss in people with retinitis pigmentosa.

NCT06787482Recruiting· Phase 1/Phase 2
Peptide therapy for retinitis pigmentosa

This trial tests a new peptide therapy for people with retinitis pigmentosa (RP), a genetic eye disease that causes vision loss. The goal is to see if the treatment is safe and can help slow or improve vision loss.

Cairo
NCT07594236Recruiting· Phase 1
Experimental Cell Therapy for Retinal Degeneration

This early-stage study tests a new cell-based treatment (C.001) for inherited retinal diseases that affect the back of the eye. The treatment may help slow vision loss or improve sight in people with geographic atrophy or Stargardt disease.

Beverly Hills, California
NCT07502664Recruiting
A study on vision and navigation in inherited retinal disease

This study is looking at how people with inherited retinal disease that affects peripheral vision see and move around. It will test a new way to measure vision and navigation to see if it can help doctors understand how the disease affects daily life.

Irvine, California

Hear when a new Stargardt Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.